Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that Chris Linthwaite , President and Chief Executive Officer, will
View HTML
Toggle Summary Fluidigm Announces Fourth Quarter and Full Year 2019 Financial Results
Fourth quarter revenue of $32.4 million Full year 2019 revenue increased 4 percent to $117.2 million ; full year mass cytometry revenue increased 23 percent Landmark Nature publication demonstrates potential clinical value of using Imaging Mass Cytometry Covance selects Fluidigm CyTOF technology to
View HTML
Toggle Summary Fluidigm Establishes Center of Excellence at NCI-Designated Comprehensive Cancer Center to Advance Imaging Mass Cytometry
New Center of Excellence to Advance Highly Multiplexed Tissue Imaging in Translational and Clinical Cancer Research SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary Fluidigm CyTOF Technology Selected by Covance to Develop Highly Multiplexed Human Immune Profiling Services
SOUTH SAN FRANCISCO, Calif. , Feb. 10, 2020 (GLOBE NEWSWIRE) -- Fluidigm (Nasdaq:FLDM) today announced that Covance, the drug development business of LabCorp® (NYSE: LH), a leading global life sciences company, has selected Fluidigm’s CyTOF® technology and the industry-leading Maxpar® Direct™
View HTML
Toggle Summary Landmark Nature Publication Demonstrates the Power of the Fluidigm Hyperion Imaging System to Identify Novel Cellular Signatures That Correlate with Distinct Clinical Outcomes
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced that a new landmark study demonstrates the potential for Imaging Mass Cytometry™ (IMC™) on the Hyperion™ Imaging System
View HTML
Toggle Summary Fluidigm Provides Preliminary Financial Results for Fourth Quarter and Fiscal Year 2019
Fourth quarter preliminary revenue of $32.0-32.4 million Fiscal year preliminary revenue of $116.7-117.2 million Mass cytometry revenue increased approximately 23 percent for the full fiscal year SOUTH SAN FRANCISCO, Calif. , Jan. 14, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ: FLDM)
View HTML
Toggle Summary MOgene Selects Fluidigm Advanta Assays and Juno System to Expand Its NGS Services Portfolio
Fluidigm microfluidics technology to fuel growth in genomics services SOUTH SAN FRANCISCO, Calif. , Jan. 13, 2020 (GLOBE NEWSWIRE) -- MOgene, a leading provider of genomic and bioinformatic services in St. Louis , today announced it has selected Fluidigm’s (NASDAQ:FLDM) Advanta™ assays and
View HTML
Toggle Summary The University of Michigan Protein Assembly Lab Selects Hyperion Imaging System for Research In Cancer Immunotherapy and Immune Phenotyping
SOUTH SAN FRANCISCO , Dec. 18, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation  (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that The University of Michigan Protein Assembly Lab , a hub for collaborative
View HTML
Toggle Summary Fluidigm Named to Greater Toronto's Top Employers for 2020
Competition Recognizes Employers with Exceptional HR Programs and Forward-Thinking Workplace Policies SOUTH SAN FRANCISCO, Calif. , Dec. 12, 2019 (GLOBE NEWSWIRE) -- Fluidigm Canada, a subsidiary of Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to
View HTML
Toggle Summary Fluidigm Expands Maxpar Antibody Portfolio for High-Multiplex Tissue Imaging
Delivering the Largest Commercially Available Collection of Pathologist‑Verified Antibodies for Imaging Mass Cytometry SOUTH SAN FRANCISCO, Calif. , Dec. 10, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), the global leader in high-multiplex single-scan tissue imaging, today announced
View HTML